Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2025 Mar;65(3):340-349.
doi: 10.1002/jcph.6143. Epub 2024 Oct 15.

Pharmacokinetics and Safety of a Novel Extended-Release Microsphere Formulation of Risperidone in Patients with Schizophrenia or Schizoaffective Disorder

David P Walling  1 , Ying Dong  2 , Robert Litman  3   4 , Wenyan Wang  5   6   7 , Chunli Liu  6   7 , Joe Tai  2 , Pinglan Liu  6   7 , Yanan Shi  5   6 , Wanhui Liu  5   6   7 , Fenghua Fu  5   6   7 , Kaoxiang Sun  5   6   7
Affiliations
Clinical Trial

Pharmacokinetics and Safety of a Novel Extended-Release Microsphere Formulation of Risperidone in Patients with Schizophrenia or Schizoaffective Disorder

David P Walling et al. J Clin Pharmacol. 2025 Mar.

Abstract

Risperidone extended-release injectable suspension (R-ERIS; marketed as RYKINDO) is a novel immediate-release version of risperidone formulated as extended-release microspheres for biweekly intramuscular injection to treat schizophrenia in adults. The pharmacokinetics (PK) and safety of R-ERIS were evaluated in a multicenter, randomized, open-label, multiple-dose study in patients with stable schizophrenia or schizoaffective disorder. Eligible patients (N = 108) 18 to 65 years old were randomized (1:1) to receive IM injections of R-ERIS 25 mg or the comparator, a biweekly risperidone long-acting injectable (BW-RLAI; marketed as RISPERDAL CONSTA) 25 mg for a total of 5 injections. The primary objective was to evaluate the relative bioavailability of active moiety (risperidone plus 9-hydroxyrisperidone) at steady state. Blood samples were analyzed for risperidone and 9-hydroxyrisperidone using a validated, specific, and sensitive liquid chromatography with tandem mass spectrometry method. Plasma concentration-time data were analyzed using non-compartmental methods. Pharmacokinetic parameters were calculated based on individual patient PK profiles. Safety was assessed using standard measures. At steady state, mean plasma concentrations of the active moiety were similar for R-ERIS and BW-RLAI. R-ERIS rapidly released risperidone after the injection without apparent lag time. Plasma active moiety levels reached steady state after the second injection of R-ERIS. The elimination of the drug was completed approximately 2 weeks earlier for R-ERIS as compared to that for BW-RLAI. R-ERIS was safe and well tolerated. Overall, R-ERIS exhibited a faster onset and offset than BW-RLAI and statistical analysis of exposure parameters demonstrated bioequivalence at steady state.

Keywords: RYKINDO; Risperidone; antipsychotics; long‐acting injectable; pharmacokinetics; schizophrenia.

PubMed Disclaimer

References

    1. Charlson FJ, Ferrari AJ, Santomauro DF, et al. Global epidemiology and burden of schizophrenia: findings from the global burden of disease study 2016. Schizophr Bull. 2018;44(6):1195‐1203.
    1. Lieslehto J, Tiihonen J, Lähteenvuo M, Tanskanen A, Taipale H. Primary nonadherence to antipsychotic treatment among persons with schizophrenia. Schizophr Bull. 2022;48(3):655–663.
    1. Salgueiro M, Segarra R. Long‐acting injectable second‐generation antipsychotics in first‐episode psychosis: a narrative review. Int Clin Psychopharmacol. 2019;34(2):5156.
    1. Tiihonen J, Mittendorfer‐Rutz E, Majak M, et al. Real‐world effectiveness of antipsychotic treatments in a nationwide cohort of 29823 patients with schizophrenia. JAMA Psychiatry. 2017;74(7):686‐693.
    1. Litman R, Naber D, Anta L, Martínez J, Filts Y, Correll CU. Personal and social functioning and health‐related quality of life in patients with schizophrenia treated with the long‐acting injectable antipsychotic risperidone ISM. Neuropsychiatr Dis Treat. 2023;19:219‐232.

Publication types

MeSH terms